Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions

Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Fioramonti, Marco, Santini, Daniele, Iuliani, Michele, Ribelli, Giulia, Manca, Paolo, Papapietro, Nicola, Spiezia, Filippo, Vincenzi, Bruno, Denaro, Vincenzo, Russo, Antonio, Tonini, Giuseppe, Pantano, Francesco
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5386748/
https://ncbi.nlm.nih.gov/pubmed/28223547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15390
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares